

# 1 **Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and** 2 **Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults**

3

4 **Authors: Patrick Yassini,<sup>1,2</sup> Mark Hutchens,<sup>3</sup> Yamuna D. Paila,<sup>4</sup> Lorraine Schoch,<sup>4</sup> Anne Aunins,<sup>4</sup> Uma**  
5 **Siangphoe,<sup>4</sup> and Robert Paris<sup>4,\*</sup>**

6 **Affiliations:** <sup>1</sup>Department of Family and Preventive Medicine, University of California, San Diego,  
7 California, USA; <sup>2</sup>Site 103, Optimal Research, San Diego, California, USA; <sup>3</sup>Optimal Research, Austin,  
8 Texas, USA; <sup>4</sup>Infectious Disease Development, Moderna, Inc., Cambridge, Massachusetts, USA.

9

## 10 **\*Corresponding Author:**

11 Robert Paris, MD

12 Head, Translational Medicine, Infectious Disease Development

13 Moderna, Inc.

14 200 Technology Square, Cambridge, MA 02139

15 Phone: 617-714-6500

16 Email: [robert.paris@modernatx.com](mailto:robert.paris@modernatx.com)

17

## 18 **Alternative Corresponding Author:**

19 Anne Aunins

20 Program Leader, COVID-19 Vaccines

21 Moderna, Inc.

22 200 Technology Square, Cambridge, MA 02139

23 Phone: 617-460-5279

24 Email: [anne.aunins@modernatx.com](mailto:anne.aunins@modernatx.com)

25 **ABSTRACT**

26 **Background.** This interim analysis of an ongoing phase I randomized clinical trial evaluated the safety,  
27 reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA  
28 (mRNA)-based vaccine encoding 2 segments of the spike protein (ie, receptor binding and N-terminal  
29 domains).

30 **Methods.** Healthy aged adults 18-55 years (n = 104) were randomized (1:1:1:1) to receive 2 doses of  
31 mRNA-1283 (10, 30, or 100 µg) or mRNA-1273 (100 µg) administered 28 days apart, or a single dose of  
32 mRNA-1283 (100 µg). Safety was assessed and immunogenicity was measured by serum neutralizing  
33 antibody (nAb) or binding antibody (bAb) responses.

34 **Results.** At the interim analysis, no safety concerns were identified and no serious adverse events,  
35 adverse events of special interest, or deaths were reported. Solicited systemic adverse reactions were  
36 more frequent with higher dose levels of mRNA-1283 than with mRNA-1273. At day 57, all dose levels of  
37 the 2-dose mRNA-1283 regimen (including the lowest dose level [10 µg]) induced robust nAb and bAb  
38 responses that were comparable to those of mRNA-1273 (100 µg).

39 **Conclusions.** mRNA-1283 was generally safe in adults, with all dose levels of the 2-dose regimen (10, 30,  
40 and 100 µg) eliciting similar immunogenicity as the 2-dose mRNA-1273 regimen (100 µg).

41 **Clinical Trials Registration:** Clinicaltrials.gov, NCT04813796

42

43 **Keywords:** severe acute respiratory syndrome coronavirus-2, COVID-19, vaccination, clinical study,

44 mRNA vaccines

45

## 46 INTRODUCTION

47 An unprecedented global response to the coronavirus disease 2019 (COVID-19) pandemic led to the  
48 rapid development of vaccines against the causative pathogen, severe acute respiratory syndrome  
49 coronavirus-2 (SARS-CoV-2). The messenger RNA (mRNA)-based vaccine mRNA-1273 (SPIKEVAX;  
50 Moderna, Inc., Cambridge, MA, USA [1]) is authorized and approved for use in many populations  
51 worldwide, available for individuals as young as  $\geq 6$  months [2]. In the phase III clinical trial in adults,  
52 mRNA-1273 had an acceptable safety profile and was efficacious against symptomatic infection and  
53 severe disease [3]. Subsequent post-authorization real-world studies provided evidence of mRNA-1273  
54 effectiveness against symptomatic infection and hospitalization [4-6] but demonstrated reduced  
55 effectiveness against infection caused by several SARS-CoV-2 variants of concern, including B.1.351  
56 (beta), AY lineages (delta), and BA lineages (omicron) [7-9]. A booster dose is recommended in  
57 individuals aged  $\geq 12$  years to maintain effectiveness [10].

58 The response to the COVID-19 pandemic demonstrated that the mRNA-lipid nanoparticle (LNP)  
59 platform affords several advantages, including expeditious development of safe and efficacious vaccines  
60 [11]; however, the refrigerated shelf life of some of these vaccines can limit vaccine distribution in  
61 certain markets [12-15]. Next-generation mRNA-based SARS-CoV-2 vaccines that offer longer  
62 refrigerated shelf life and/or are immunogenic at a lower dose than mRNA-1273 may enable increased  
63 mRNA-based vaccine coverage worldwide, potentially further preventing COVID-19-associated  
64 morbidity and mortality.

65 mRNA-1283 is one such investigational vaccine candidate, aiming to elicit neutralizing antibodies  
66 by encoding 2 segments of the SARS-CoV-2 S protein, including the receptor binding domain (RBD) and  
67 the N-terminal domain (NTD) regions, which contain key SARS-CoV-2 neutralization epitopes [16, 17].  
68 Comparatively, mRNA-1273 encodes the full-length SARS-CoV-2 S protein. A preclinical evaluation of  
69 mRNA-1283 in mice demonstrated comparable protection and immunogenicity characteristics as mRNA-

70 1273 with potential dose-sparing properties, while indicating that the shorter mRNA length within  
71 mRNA-1283 may facilitate longer storage under refrigeration than mRNA-1273 [18].

72 Here, we report preliminary safety, reactogenicity, and immunogenicity results for mRNA-1283  
73 from a phase I, randomized, observer-blind, dose-ranging study in healthy adults aged 18-55 years.

74

## 75 **METHODS**

### 76 **Trial Design and Participants**

77 This is an ongoing phase I, randomized, observer-blind study being conducted at 5 sites in the United  
78 States to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1283 (NCT04813796).  
79 Eligible participants were healthy adults (aged 18-55 years) with negative SARS-CoV-2 serology, no  
80 known history of SARS-CoV-2 infection or exposure to SARS-CoV-2 or COVID-19 in the previous 30 days,  
81 and were not previously administered any coronavirus vaccine. A full list of the study inclusion/exclusion  
82 criteria is in the **Supplement**.

83 Three dose levels of mRNA-1283 (10 µg, 30 µg, and 100 µg) and 1 dose level of mRNA-1273 (100  
84 µg) were administered on a 2-dose schedule with 28 days between doses; the mRNA-1283 100-µg dose  
85 level was also assessed as a single-dose regimen. Participants were randomly assigned in parallel  
86 (1:1:1:1:1) using interactive response technology (**Figure S1**; see the **Supplement** for details).  
87 Participants were followed for safety, reactogenicity, and immunogenicity, with a planned interim  
88 analysis to evaluate data on ≥80 participants through day 57. After the interim analysis, participants  
89 who received the single mRNA-1283 100-µg dose were offered an additional injection of mRNA-1273  
90 (100 µg).

91 The protocol was approved by the central institutional review board (Advarra, Inc; Columbia,  
92 MD) and the study was conducted in accordance with the protocol, applicable laws and regulatory  
93 requirements, the International Council for Harmonization Good Clinical Practice guidelines, and the

94 ethical principles derived from the Declaration of Helsinki and Council for International Organizations of  
95 Medical Sciences International Ethical Guidelines. All participants provided written informed consent  
96 before any study procedures were conducted.

97

## 98 **Vaccines**

99 mRNA-1283 is an mRNA-LNP vaccine encoding for a chimeric protein (NTD-RBD-HATM) comprising the  
100 SARS-CoV-2 S protein NTD and RBD, linked together by a flexible peptide linker and anchored to a 23-  
101 amino acid transmembrane domain from influenza hemagglutinin (HATM). mRNA-1273 is an mRNA-LNP  
102 vaccine encoding for the full-length, 2-proline prefusion stabilized SARS-CoV-2 S protein (S2P). Placebo  
103 was a 0.9% sodium chloride (normal saline) injection.

104 Vaccines were provided as a sterile liquid for injection at 0.2 mg/mL (mRNA-1273) or 0.5 mg/mL  
105 (mRNA-1283; diluted with 0.9% saline to the appropriate dose) concentrations; all vaccines were  
106 administered at 0.5-mL dose volume into the deltoid muscle. For the 2-dose regimen, each dose level of  
107 mRNA-1283 or mRNA-1273 was administered 28 days apart (day 1 and day 29). The 1-dose regimen of  
108 mRNA-1283 had placebo administered on day 1 and mRNA-1283 (100 µg) administered on day 29.

109

## 110 **Objectives and Endpoints**

111 The primary objective was to evaluate the safety and reactogenicity of mRNA-1283 (10 µg, 30 µg, and  
112 100 µg) and mRNA-1273 (100 µg), each administered on a 2-dose schedule (28 days apart), and mRNA-  
113 1283 (100 µg) administered as a single dose. Safety endpoints included solicited local (ie, pain,  
114 erythema, or hardness at the injection site; or axillary swelling or tenderness) and systemic (ie,  
115 headache, fatigue, myalgia, arthralgia, nausea, chills, and fever) adverse reactions (ARs) ≤7 days of each  
116 dose, as recorded by participants using an electronic diary; safety laboratory abnormalities ≤7 days of  
117 each dose (see the **Supplement**); unsolicited adverse events (AEs) ≤28 days of each dose; and any

118 serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to discontinuation, and AEs of special  
119 interest (AESIs) from day 1 to end of study. Safety data were monitored by an unblinded, independent  
120 data and safety monitoring board, a blinded internal safety team, and a blinded safety oversight team.

121 This report summarizes interim safety assessments after a median of 127 days (>4 months) after dose 2.

122 Secondary objectives were to evaluate the immunogenicity of mRNA-1283 administered as a 2-  
123 dose schedule (10 µg, 30 µg, and 100 µg) or a single dose schedule (100 µg) and mRNA-1273  
124 administered as a 2-dose schedule (100 µg) as measured by nAb titer or level of binding antibody (bAb).  
125 Serum nAb titers were measured by a validated lentivirus assay [19, 20] (PsVN assay; see the  
126 **Supplement**) against Wuhan-Hu-1 (with D614G mutation) SARS-CoV-2 or the B.1.351 (beta) variant with  
127 a 50% inhibitory dilution; titers against Wuhan-Hu-1 (without D614G mutation) were also measured by a  
128 validated live virus 50% microneutralization assay [21] (see the **Supplement**). Levels of serum bAbs  
129 against Wuhan-Hu-1 SARS-CoV-2 were measured by a SARS-CoV-2 Meso Scale Discovery (MSD) 4-PLEX  
130 assay (modified 3-PLEX assay [22]; see the **Supplement**). For this interim analysis, only assessments on  
131 samples collected on day 1 (baseline) and days 29, 36, and 57 were summarized.

132

### 133 **Statistical Analyses**

134 Sample size determination is described in the **Supplement**. Safety was assessed in the safety and  
135 solicited safety populations (defined in the **Supplement**). All safety analyses were summarized according  
136 to the actual vaccine received. Safety was descriptively analyzed as counts and percentages.

137 Immunogenicity was assessed in the per-protocol population (defined in the **Supplement**). For  
138 each vaccine group, the geometric mean titer (GMT) or levels of SARS-CoV-2 nAb and bAb were  
139 computed at each sampling time point, as well as the geometric mean fold rise (GMFR) of titers or levels  
140 from baseline to each post-baseline time point; values were summarized alongside corresponding 95%  
141 confidence intervals (CIs) calculated based on the *t* distribution of the log-transformed values, then

142 back-transformed to the original scale for presentation. The geometric mean ratio (GMR) calculated as  
143 the mean of the difference in nAb titers and bAb levels between mRNA-1283 and mRNA-1273 and the  
144 corresponding 2-sided 95% CI were provided. Percentages of participants with vaccine seroresponse  
145 were also calculated by time point and vaccine group alongside 2-sided 95% CIs using the Clopper-  
146 Pearson method. Seroresponse was defined as an increase in titer or level from less than the lower limit  
147 of quantification [LLOQ] at baseline to  $\geq$ LLOQ, or a  $\geq$ 4-fold increase over baseline in participants with  
148 pre-existing baseline titers or levels that were  $\geq$ LLOQ. All analyses were performed using SAS software,  
149 version 9.4 (SAS Institute).

150

## 151 **RESULTS**

### 152 **Participants**

153 Between March 11, 2021, and July 28, 2021, a total of 104 participants were randomly assigned to  
154 receive 2 doses of mRNA-1283 (10  $\mu$ g, n=21; 30  $\mu$ g, n=22; 100  $\mu$ g, n=21), 1 dose of mRNA-1283 (100  $\mu$ g;  
155 n=18), or 2 doses of mRNA-1273 100  $\mu$ g (n=22). All randomly assigned participants received dose 1 and  
156 75 (91.5%) and 20 participants (90.9%) received dose 2 in the mRNA-1283 and mRNA-1273 groups,  
157 respectively (**Figure 1**). Overall, 68 participants (82.9%) in the mRNA-1283 groups and 18 participants  
158 (81.8%) in the mRNA-1273 group were included in the per-protocol immunogenicity population for this  
159 interim analysis. Participant baseline demographics are summarized in **Table 1**.

160

### 161 **Safety**

#### 162 ***Solicited Local and Systemic Adverse Reactions***

163 Across mRNA-1283 groups, solicited local ARs  $\leq$ 7 days of vaccination were reported by 6-18 participants  
164 (33.3-85.7%) after dose 1 and 12-19 participants (73.7-90.5%) after dose 2 (**Figure 2A**); 21 (95.5%) and

165 19 mRNA-1273 recipients (95.0%) reported solicited local ARs after dose 1 and dose 2, respectively. The  
166 majority of solicited local ARs were mild to moderate (grades 1 and 2), with no grade 4 events reported.  
167 Pain at the injection site was most common, reported by >70% of participants across vaccine groups  
168 following dose 2. The median duration of solicited local ARs was 2-3 days after mRNA-1283 and 3 days  
169 after mRNA-1273.

170 After dose 1, solicited systemic ARs  $\leq 7$  days of vaccination were reported by 7-12 participants  
171 (38.9-54.5%) across mRNA-1283 groups and 15 participants (68.2%) in the mRNA-1273 group (**Figure**  
172 **2B**). Systemic ARs were more frequent after dose 2, reported by 9-21 participants (60-100%) across  
173 mRNA-1283 groups and 19 participants (95.0%) in the mRNA-1273 group. Headache, fatigue, and  
174 myalgia were most frequent. Solicited systemic ARs were predominantly mild to moderate after dose 1  
175 of mRNA-1283, but increased in severity after dose 2, with 3 to 12 (20.0-63.2%) and 1 to 10 participants  
176 (6.7-47.6%) reporting grade 2 and 3 events, respectively; no grade 4 events were reported. Increased  
177 severity was predominantly reported at higher mRNA-1283 dose levels. Fever and chills were largely  
178 reported after dose 2 and for participants who received mRNA-1283 at higher dose levels. The median  
179 duration of solicited systemic ARs was 2-3 days after mRNA-1283 and 2 days after mRNA-1273.

180

### 181 ***Unsolicited Adverse Events***

182 No prespecified study pause rules were met, and no SAEs, AESIs, severe AEs, or fatal AEs were reported  
183  $\leq 28$  days after any dose of mRNA-1283 or mRNA-1273. Unsolicited treatment-emergent AEs (TEAEs)  
184 were reported by 4-9 participants (22.2-42.9%) across mRNA-1283 groups and 7 participants (31.8%) in  
185 the mRNA-1273 group (**Table 2**). Overall, 2-4 (9.5-19.0%) and 4 participants (18.2%) reported unsolicited  
186 TEAEs considered related to either mRNA-1283 or mRNA-1273, respectively. Across mRNA-1283 groups,  
187 a total of 2-3 participants (9.1-14.3%) reported MAAEs; 2 participants reported vaccine-related MAAES  
188 (n=1, allergic dermatitis [mRNA-1283 30  $\mu$ g]; n=1, headache, fatigue, arthralgia, and myalgia [mRNA-



189 1283 100 µg]). Three mRNA-1273 recipients (13.6%) reported MAAEs, and 1 MAAE (vomiting, 4.5%) was  
190 considered related to vaccination. One participant in the mRNA-1273 group discontinued vaccination  
191 because of transient elevation in liver transaminase levels 7 days after dose 1 that subsequently  
192 returned to normal, which was considered vaccine-related. Clinical laboratory findings are presented in  
193 the **Supplement**.

194

## 195 **Immunogenicity**

### 196 ***Serum Neutralizing Antibodies Against SARS-CoV-2***

197 For the 2-dose regimen, pseudovirus nAb GMTs to D614G SARS-CoV-2 increased from baseline  
198 after dose 1 (day 29) of mRNA-1273 (100 µg) and all dose levels of mRNA-1283 (10 µg, 30 µg, and 100  
199 µg; **Figure 3A**). At 28 days following dose 2 (day 57), pseudovirus nAb GMTs (95% CI) for all dose levels  
200 of mRNA-1283 administered were comparable to those of mRNA-1273 (mRNA-1283, 10 µg: 1370 [888-  
201 2112], 30 µg: 1091 [645-1846], and 100 µg: 1679 [1133-2487]; mRNA-1273: 1190 [826-1713]; **Figure 3A**;  
202 **Table S1**); generally similar findings were observed against Wuhan-Hu-1 (without D614G mutation) with  
203 the live-virus microneutralization assay (**Figure S2**; **Table S1**). As measured by pseudovirus nAb titers  
204 against D614G, seroresponse at day 57 occurred in 100% of participants in all groups who received 2  
205 doses of mRNA vaccines. Geometric mean ratios (95% CI; **Table S1**) of GMTs for 2-dose regimens of  
206 mRNA-1283 versus mRNA-1273 at day 57 were 1.15 (0.67-1.98), 0.92 (0.50-1.70), and 1.41 (0.84-2.38)  
207 for the mRNA-1283 10-µg, 30-µg, and 100-µg dose levels, respectively. For the 1-dose mRNA-1283  
208 regimen (placebo + mRNA-1283 100 µg), a slight increase from baseline was observed 28 days after  
209 mRNA-1283 administration (day 57) but remained lower than 2-dose regimens; the GMR (95% CI) at day  
210 57 relative to 2 doses of mRNA-1273 was 0.05 (0.01-0.18) and seroresponse occurred in 28.6% of  
211 participants.

212 After dose 2, all 2-dose mRNA-1283 groups (10 µg, 30 µg, and 100 µg) had comparable  
213 pseudovirus nAb GMTs to B.1.351 compared with mRNA-1273 (**Figure 3B; Table S1**). The 1-dose mRNA-  
214 1283 100 µg regimen did not induce a substantial nAb response to B.1.351 at day 57 (**Figure 3B**). At day  
215 57, seroresponse to B.1.351 occurred in 61.1%-85.0% and 66.7% of participants in the 2-dose mRNA-  
216 1283 groups and mRNA-1273 group, respectively (**Table S1**); 14.3% of participants in the 1-dose mRNA-  
217 1283 regimen had a seroresponse to B.1.351.

218

### 219 ***Serum Binding Antibodies Against SARS-CoV-2***

220 For the 2-dose regimens, bAb immunoglobulin G (IgG) responses to Wuhan-Hu-1 full-length S protein  
221 were low or undetectable at baseline for all vaccine groups and increased after dose 1 of mRNA-1283  
222 (10 µg, 30 µg, and 100 µg) and mRNA-1273 (100 µg; **Figure 4A**). At 28 days after dose 2 (day 57), bAb  
223 responses were generally comparable between mRNA-1283 and mRNA-1273 regardless of dose level  
224 (**Figure 4A; Table S2**), with GM levels (95% CI) reported as 322,671 (232,477-447,858), 280,454  
225 (196,077-401,139), 416,620 (312,082-556,175), and 303,004 (242,750-378,212) for the mRNA-1283 10-  
226 µg, 30-µg, and 100-µg and mRNA-1273 100-µg dose levels, respectively. Seroresponse at day 57  
227 occurred in 100% of mRNA-1283 (all dose levels) or mRNA-1273 100 µg recipients. Similar trends were  
228 observed for bAb IgG responses to Wuhan-Hu-1 S protein RBD and NTD (**Figure 4B-C; Table S2**), with all  
229 dose levels of mRNA-1283 eliciting similar responses to either domain at day 57 as compared with  
230 mRNA-1273; seroresponses were observed in 100% of 2-dose vaccine recipients at day 57.

231 The 1-dose mRNA-1283 regimen (placebo + mRNA-1283 100 µg) showed an increase from  
232 baseline in bAb responses to Wuhan-Hu-1 S protein, RBD, and NTD at 28 days after mRNA-1283 was  
233 administered (day 57). GM levels (95% CI) were 15,396 (4855-48,820) for S protein, 9700 (3110-30,252)  
234 for RBD, and 296 (95-919) for NTD; seroresponse against S protein, RBD, and NTD was 92.9%.

235

236 **DISCUSSION**

237           Here, we presented interim safety and immunogenicity findings of a phase I clinical study in  
238 healthy adults of a next-generation SARS-CoV-2 vaccine candidate (mRNA-1283), which encodes the  
239 SARS-CoV-2 S protein RBD and NTD segments versus full-length S protein encoded by mRNA-1273.  
240 Preliminary findings indicate that all mRNA-1283 dose levels (10 µg, 30 µg, and 100 µg) administered on  
241 a 2-dose schedule (28 days apart) were generally safe and elicited robust immune responses that were  
242 comparable to mRNA-1273 (100 µg). The lowest investigated mRNA-1283 dose level (10 µg) had the  
243 most favorable tolerability profile and induced robust nAb and bAb responses to SARS-CoV-2 after dose  
244 2 that were similar to those of mRNA-1273. Overall, these findings suggest that a 2-dose regimen of  
245 mRNA-1283 at a lower dose level may achieve similar vaccine efficacy to mRNA-1273.

246           No safety concerns were identified and no deaths, SAEs, or AESIs were reported. Both local and  
247 systemic ARs after dose 1 of mRNA-1283 were generally mild to moderate, characterized by pain at the  
248 injection site, headache, fatigue, and myalgia. After dose 2, solicited systemic ARs generally increased in  
249 frequency and severity. Overall, compared with mRNA-1273, solicited systemic ARs occurred more  
250 frequently with higher dose levels of mRNA-1283.

251           Following a 2-dose schedule, all mRNA-1283 dose levels (including the lowest dose [10 µg])  
252 induced nAb responses after dose 2 to prototype SARS-CoV-2 that were comparable to mRNA-1273 (100  
253 µg). Notably, the pseudovirus nAb responses after dose 2 of mRNA-1273 in this study align with those  
254 among adults in the pivotal phase III trial [23], wherein 2 doses of mRNA-1273 (100 µg) administered 28  
255 days apart were efficacious against symptomatic COVID-19 infection and severe COVID- 19 [3, 24].  
256 Additionally, levels of bAb responses to full-length S protein, NTD, and RBD were similar between  
257 mRNA-1273 and all mRNA-1283 dose levels at 28 days following dose 2. Our interim phase I findings  
258 raise the possibility that a lower mRNA-1283 dose administered via a 2-dose regimen might achieve  
259 similar efficacy and effectiveness as mRNA-1273 among adults. Notably, although the 1-dose regimen of

260 mRNA-1283 (100 µg) induced bAb responses at 28 days, levels remained lower than those for 2-dose  
261 mRNA-1283 and mRNA-1273 regimens; further, neutralizing responses to D614G SARS-CoV-2 remained  
262 low after 1 dose, together supporting a 2-dose schedule of mRNA-1283. These data suggest that higher  
263 mRNA-1283 dose levels do not result in higher nAb responses; however, whether this finding extends to  
264 T-cell responses is currently being assessed. Because the severity of solicited systemic ARs was increased  
265 at the mRNA-1283 100-µg dose level, it remains possible that increased systemic inflammation at higher  
266 dose levels, potentially through complex interactions of type 1 interferons or other innate immune  
267 effector molecules, may suppress B- and/or T-cell responses and warrants further study [25-27]. The 2-  
268 dose schedule of mRNA-1283 (all dose levels) and mRNA-1273 also elicited comparable nAb responses  
269 to the SARS-CoV-2 B.1.351 variant after dose 2; further studies evaluating variant-specific modifications  
270 of mRNA-1283 as a booster dose are currently underway (NCT05137236) [28].

271           This study was strengthened by its randomized design, which allowed for descriptive  
272 comparisons to mRNA-1273, a widely administered SARS-CoV-2 vaccine with known efficacy in  
273 preventing COVID-19. A limitation was the small number of participants enrolled. This interim report  
274 presents findings through day 57 of an ongoing phase I trial that will continue to evaluate mRNA-1283  
275 safety and immunogenicity, including long-term antibody responses to inform on immune response  
276 durability, which remains important amid reports of waning immunity within 6 months of mRNA-1273  
277 primary vaccination [29, 30].

278           In conclusion, these preliminary findings support the continued evaluation of mRNA-1283, a  
279 next-generation SARS-CoV-2 vaccine. All dose levels of mRNA-1283 administered via a 2-dose regimen,  
280 28 days apart, were generally safe in healthy adults aged 18-55 years, with the lowest dose level (10 µg)  
281 inducing comparable immunogenicity to the approved mRNA-1273 100 µg regimen. Clinical evaluation  
282 of mRNA-1283 is ongoing to assess the applicability of booster doses at lower dose levels and immune  
283 responses against other SARS-CoV-2 variants.

284 **Funding**

285 This work was supported by Moderna, Inc.

286

287 **Data Sharing Statement**

288 Upon request, and subject to review, Moderna, Inc. will provide the data that support the findings of

289 this study. Subject to certain criteria, conditions, and exceptions, Moderna, Inc. may also provide access

290 to the related individual anonymized participant data.

291

292 **Acknowledgments**

293 The authors would like to acknowledge Dr. Murray Kimmel (Optimal Research, Melbourne, Florida,

294 USA), Dr. Daniel Brune (Optimal Research, Peoria, Illinois, USA), and Dr. Randall Severance (AES/Optimal

295 Research, Chandler, Arizona, USA) for their contributions to the study. Medical writing and editorial

296 assistance were provided by Emily Stackpole, PhD, of MEDiSTRAVA in accordance with Good Publication

297 Practice (GPP3) guidelines, funded by Moderna, Inc., and under the direction of the authors. Potential

298 conflicts of Interest: Y. D. P., L. S., A. A., U. S., and R. P. are employees of and shareholders in

299 Moderna, Inc. P. Y. and M. H. have no conflicts to declare.

300

301

## 302 REFERENCES

- 303 1. FDA. Package Insert - SPIKEVAX. <https://www.fda.gov/media/155675/download>. Date accessed 15 March  
304 2022. **2022**.
- 305 2. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against  
306 COVID-19. Available at: [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3)  
307 [recommendation-mRNA-1273-2021.3](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-1273-2021.3). Accessed October 12.
- 308 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J*  
309 *Med* **2021**; 384(5): 403-16.
- 310 4. Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19:  
311 Interim results from a prospective observational cohort study. *Lancet Reg Health Am* **2021**: 100134.
- 312 5. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the  
313 B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **2021**.
- 314 6. Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health  
315 Care Personnel. *N Engl J Med* **2021**; 385(25): e90.
- 316 7. Bruxvoort KJ, Sy LS, Qian L, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging  
317 variants of SARS-CoV-2: test negative case-control study. *BMJ* **2021**; 375: e068848.
- 318 8. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness  
319 against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* **2021**.
- 320 9. Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta  
321 variants. *Nat Med* **2022**.
- 322 10. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against  
323 COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among  
324 Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August  
325 2021-January 2022. *MMWR Morb Mortal Wkly Rep* **2022**; 71(7): 255-63.
- 326 11. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and  
327 clinical translation. *Nat Rev Drug Discov* **2021**; 20(11): 817-38.
- 328 12. Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. *Vaccines*  
329 **2021**; 9(9): 1033.
- 330 13. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19  
331 vaccines: production, affordability, allocation, and deployment. *Lancet* **2021**; 397(10278): 1023-34.
- 332 14. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-  
333 income countries. *NPJ Vaccines* **2021**; 6(1): 54.
- 334 15. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of  
335 mRNA vaccine stability. *J Pharm Sci* **2021**; 110(3): 997-1001.
- 336 16. Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients  
337 define multiple targets of vulnerability. *Science* **2020**; 369(6504): 643-50.
- 338 17. Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2  
339 spike. *Nature* **2020**; 584(7821): 450-6.
- 340 18. Stewart-Jones GBE, Elbashir SM, Wu K, et al. Development of SARS-CoV-2 mRNA vaccines encoding spike  
341 N-terminal and receptor binding domains. *bioRxiv* **2022**: 2022.10.07.511319.
- 342 19. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies  
343 elicited by ancestral spike vaccines. *Cell Host Microbe* **2021**.
- 344 20. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in  
345 healthy adults: an interim analysis. *Nat Med* **2021**.
- 346 21. Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the  
347 safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine* **2021**; 39(20): 2791-9.
- 348 22. Chu L, Vrbicky K, Montefiori D, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an  
349 open-label phase 2 trial. *Nat Med* **2022**; 28(5): 1042-9.
- 350 23. El Sahly HM, Baden LR, Essink B, et al. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3  
351 COVE Trial. *J Infect Dis* **2022**.

- 352 24. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of  
353 blinded phase. *N Engl J Med* **2021**.
- 354 25. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. *Nat Rev*  
355 *Immunol* **2015**; 15(2): 87-103.
- 356 26. Darrah PA, Hegde ST, Patel DT, et al. IL-10 production differentially influences the magnitude, quality, and  
357 protective capacity of Th1 responses depending on the vaccine platform. *J Exp Med* **2010**; 207(7): 1421-  
358 33.
- 359 27. Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in  
360 humans. *Nature* **2021**; 596(7872): 410-6.
- 361 28. ClinicalTrials.gov. A study to evaluate the immunogenicity and safety of mRNA-1283 COVID-19 vaccine  
362 boosters. Available at: <https://clinicaltrials.gov/ct2/show/NCT05137236>. Accessed January 23.
- 363 29. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in  
364 healthy adults: an interim analysis. *Nat Med* **2021**; 27(11): 2025-31.
- 365 30. Pegu A, O'Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against  
366 SARS-CoV-2 variants. *Science* **2021**; 373(6561): 1372-7.
- 367

368 **Table 1. Participant baseline demographics (safety population)**

	mRNA-1283				mRNA-1273
	10 µg (n=21)	30 µg (n=22)	100 µg (n=21)	Placebo + 100 µg (n=18)	100 µg (n=22)
<b>Age, y</b>					
Mean ± SD	38.1 ± 9.5	34.8 ± 10.4	34.8 ± 10.8	33.7 ± 10.4	42.0 ± 10.3
Median (range)	41.0 (23-51)	30.5 (21-54)	36.0 (19-51)	30.5 (19-49)	43.0 (22-55)
<b>Sex, n (%)</b>					
Male	9 (42.9)	13 (59.1)	12 (57.1)	12 (66.7)	14 (63.6)
Female	12 (57.1)	9 (40.9)	9 (42.9)	6 (33.3)	8 (36.4)
<b>Race, n (%)</b>					
White	15 (71.4)	16 (72.7)	16 (76.2)	10 (55.6)	16 (72.7)
Black/African American	1 (4.8)	2 (9.1)	1 (4.8)	0	1 (4.5)
Asian	0	1 (4.5)	2 (9.5)	1 (5.6)	1 (4.5)
American Indian or Alaska Native	0	0	0	1 (5.6)	0
Native Hawaiian or Other Pacific Islander	0	0	0	1 (5.6)	0
Multiracial	1 (4.8)	0	0	2 (11.1)	0
Other	0	0	0	0	0
Not reported	4 (19.0)	3 (13.6)	2 (9.5)	3 (16.7)	4 (18.2)
<b>Ethnicity, n (%)</b>					
Not Hispanic or Latino	14 (66.7)	15 (68.2)	16 (76.2)	13 (72.2)	14 (63.6)
Hispanic or Latino	7 (33.3)	7 (31.8)	5 (23.8)	4 (22.2)	7 (31.8)
Not reported	0	0	0	1 (5.6)	1 (4.5)



**Weight, kg**

Mean  $\pm$  SD                                      81.3  $\pm$  14.4      76.9  $\pm$  17.1      73.4  $\pm$  15.5      82.5  $\pm$  19.9      81.5  $\pm$  11.9

**Height, cm**

Mean  $\pm$  SD                                      173.5  $\pm$  11.2      171.8  $\pm$  10.0      172.1  $\pm$  12.1      175.0  $\pm$  9.2      172.3  $\pm$  8.4

**BMI, kg/m<sup>2</sup>**

Mean  $\pm$  SD                                      27.0  $\pm$  3.8      25.9  $\pm$  4.1      24.6  $\pm$  3.3      26.7  $\pm$  4.5      27.5  $\pm$  3.6

---

369 All randomly assigned participants who received dose 1 of the study vaccination were included in the safety  
370 population.

371 Abbreviations: BMI, body mass index; mRNA, messenger RNA; SD, standard deviation.

372

**Table 2. Summary of unsolicited TEAEs through 28 days following any vaccination (safety population)**

n (%)	mRNA-1283				mRNA-1273
	10 µg (n=21)	30 µg (n=22)	100 µg (n=21)	Placebo + 100 µg (n=18)	100 µg (n=22)
<b>All unsolicited TEAEs</b>					
All AEs	8 (38.1)	9 (40.9)	9 (42.9)	4 (22.2)	7 (31.8)
SAEs	0	0	0	0	0
Fatal AEs	0	0	0	0	0
MAAEs	3 (14.3)	2 (9.1)	2 (9.5)	2 (11.1)	3 (13.6)
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)
AEs leading to study discontinuation	0	0	0	0	0
Severe	0	0	0	0	0
AESIs	0	0	0	0	0
<b>Related unsolicited TEAEs</b>					
All AEs	2 (9.5)	4 (18.2)	4 (19.0)	2 (11.1)	4 (18.2)
SAEs	0	0	0	0	0
Fatal AEs	0	0	0	0	0
MAAEs	0	1 (4.5)	1 (4.8)	0	1 (4.5)
AEs leading to vaccination discontinuation	0	0	0	0	1 (4.5)
AEs leading to study discontinuation	0	0	0	0	0

Severe	0	0	0	0	0
AESIs	0	0	0	0	0

---

A TEAE is any event not present before exposure to study vaccination or any event already present that worsened in intensity or frequency after exposure.

Abbreviations: AE, adverse event; AESI, adverse event of special interest; MAAE, medically attended adverse event; mRNA, messenger RNA; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

## FIGURE LEGENDS

**Figure 1.** Participant disposition. One participant in the mRNA-1273 100- $\mu$ g group discontinued vaccination because of an adverse event, which was considered related to study vaccination. All randomly assigned participants who received dose 1 of the study vaccination were included in the safety population. Reasons for exclusion from the per-protocol immunogenicity population are described in the **Supplementary Materials**.

Abbreviation: mRNA, messenger RNA.

**Figure 2.** Solicited (A) local and (B) systemic adverse reactions within 7 days of each dose. Percentages are based on participants in the solicited safety population, consisting of all randomly assigned participants receiving  $\geq 1$  dose and contributing any solicited adverse reaction data. Number of participants in the dose 1 solicited safety population: mRNA-1283 10  $\mu$ g, n=21; mRNA-1283 30  $\mu$ g, n=22; mRNA-1283 100  $\mu$ g, n=21; placebo + mRNA-1283 100  $\mu$ g, n=18; and mRNA-1273 100  $\mu$ g, n=22. Number of participants in the dose 2 solicited safety population: mRNA-1283 10  $\mu$ g, n=19; mRNA-1283 30  $\mu$ g, n=20; mRNA-1283 100  $\mu$ g, n=21; placebo + mRNA-1283 100  $\mu$ g, n=15; and mRNA-1273 100  $\mu$ g, n=20.

Abbreviation: mRNA, messenger RNA.

**Figure 3.** Pseudovirus neutralizing antibody ID<sub>50</sub> titers against (A) Wuhan-Hu-1 (with D614G mutation) SARS-CoV-2 or (B) B.1.351 variant through day 57. Neutralizing antibody titers on the pseudovirus neutralization assay at ID<sub>50</sub> (log scale) are shown for those participants in the per-protocol immunogenicity population. In both panels, boxplots are based on log-transformed values; boxes and horizontal bars denote IQR range and ID<sub>50</sub>, respectively, with whisker end points equal to the values below or above the median at 1.5 times the IQR. Dots represent individual results and the dotted lines represent either the LLOQ or ULOQ. Antibody values reported as below the LLOQ were replaced by 0.5 x

LLOQ, whereas values greater than the ULOQ were converted to the ULOQ if the actual values were unavailable. In panel A, the LLOQ was 18.5 ( $\log_{10}[\text{LLOQ}] = 1.267$ ) and the ULOQ was 45118 ( $\log_{10}[\text{ULOQ}] = 4.654$ ). In panel B, the LLOQ was 19.5 ( $\log_{10}[\text{LLOQ}] = 1.290$ ) and the ULOQ was 385.7 ( $\log_{10}[\text{ULOQ}] = 2.586$ ).

Abbreviations: ID<sub>50</sub>, 50% inhibitory dose; IQR, interquartile range; LLOQ, lower limit of quantification; mRNA, messenger RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ULOQ, upper limit of quantification.

**Figure 4.** Binding antibody levels through day 57 specific to Wuhan-Hu-1 SARS-CoV-2 (A) S protein or (B) RBD. Binding IgG antibody levels specific to Wuhan-Hu-1 SARS-CoV-2 S protein (panel A), RBD (panel B), or NTD (panel C) by MSD 4-PLEX assay are shown for those participants in the per-protocol immunogenicity population. In both panels, boxplots are based on log-transformed values; boxes and horizontal bars denote IQR range and GM, respectively, with whisker end points equal to the values below or above the median at 1.5 times the IQR. Individual results are represented as dots and the dotted lines represent either the LLOQ or ULOQ. Antibody values reported as below the LLOQ were replaced by 0.5 x LLOQ, whereas values greater than the ULOQ were converted to the ULOQ if actual values were unavailable. In panel A, the LLOQ was 23 ( $\log_{10}[\text{LLOQ}] = 1.362$ ) and the ULOQ was 14000000 ( $\log_{10}[\text{ULOQ}] = 7.146$ ). In panel B, the LLOQ was 19 ( $\log_{10}[\text{LLOQ}] = 1.279$ ) and the ULOQ was 6000000 ( $\log_{10}[\text{ULOQ}] = 6.778$ ).

Abbreviations: ID<sub>50</sub>, 50% inhibitory dose; IgG, immunoglobulin G; IQR, interquartile range; LLOQ, lower limit of quantification; mRNA, messenger RNA; MSD, Meso Scale Discovery; NTD, N-terminal domain; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ULOQ, upper limit of quantification.

Figure 1.






Figure 2.



**Figure 3.**


**A**

**Pseudovirus Neutralizing Antibodies Against Wuhan-Hu-1 (with D614G)**



**B**

**Pseudovirus Neutralizing Antibodies Against B.1.351**






**Figure 4.**


**A**

**Wuhan-Hu-1 Spike Binding Antibodies**



**B**

**Wuhan-Hu-1 Receptor Binding Domain Binding Antibodies**



**C**

**Wuhan-Hu-1 N-terminal Domain Binding Antibodies**

